0000000000960130

AUTHOR

Eduardo Martínez De Dueñas

showing 5 related works from this author

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

2017

Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We ident…

Mama -- Càncer -- Aspectes genètics0301 basic medicineCancer ResearchPathologyReceptor ErbB-2DiseaseTranscriptome0302 clinical medicineGene expressionSurvival outcomes Letrozole Concordance Predictor Disease Impact Brain Cells Women RiskSurvival outcomesDiseaseNeoplasm Metastasisskin and connective tissue diseasesRegulation of gene expressionAged 80 and overBrainCells WomenMiddle AgedPrognosisMetastatic breast cancerNeoplasm ProteinsGene Expression Regulation NeoplasticImpactOncology030220 oncology & carcinogenesisLetrozoleFemaleRiskAdultmedicine.medical_specialtymedicine.drug_classBreast NeoplasmsBiologyArticle03 medical and health sciencesBreast cancerConcordancemedicineBiomarkers TumorHumansGeneAgedEstrogensmedicine.disease030104 developmental biologyEstrogenNeoplasm Recurrence LocalTranscriptomePredictor
researchProduct

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positiv…

2015

Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m2, respectively, × four cycles), followed by docetaxel (100 mg/m2 × four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m2, respectively, × four cycles), followed by capecitabine (1,250 mg/m2 twice a day on days 1 to 14, × four cycles; ET-X); all regime…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsDocetaxelDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineAdjuvant therapyHumansCyclophosphamideCapecitabineAgedEpirubicinNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryRegimenTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantFluorouracilLymphatic MetastasisFemaleTaxoidsFluorouracilLymph NodesbusinessFollow-Up Studiesmedicine.drugEpirubicinJournal of Clinical Oncology
researchProduct

Evaluación del grado de conversión de los receptores HER2, RE y RPg entre el cáncer de mama primario y sus respectivas metástasis

2017

Introducción: Tradicionalmente, las decisiones terapéuticas tanto del cáncer de mama precoz como de los estadios avanzados se han basado en los marcadores predictivos del tumor primario, tales como el receptor de estrógeno (RE), el receptor de progesterona (RPg) y el receptor 2 del factor de crecimiento epidérmico humano (HER2), asumiendo que éstos permanecían inmutables a nivel de la recaída metastásica. Objetivos: El objetivo general de esta tesis era investigar si el estado de los receptores HER2, RE y RPg realmente puede cambiar durante la progresión del cáncer de mama y profundizar en las causas y en el impacto clínico de dichos cambios. El objetivo principal era determinar la tasa de …

Oncología Médica320713Receptor de progesterona (RP)MetástasisConversión:CIENCIAS DE LA VIDA [UNESCO]Cáncer de mamaReceptoresHER2UNESCO::CIENCIAS DE LA VIDADiscordanciaReceptor estrogénico (RE)320101
researchProduct

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-…

2019

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen. Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of sta…

Adult0301 basic medicineSubset AnalysisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAxillary lymph nodesmedicine.medical_treatmentTriple Negative Breast NeoplasmsDisease-Free SurvivalCapecitabineYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineCapecitabineNeoadjuvant therapyTriple-negative breast cancerAgedChemotherapyTaxanebusiness.industryHazard ratioMiddle AgedNeoadjuvant Therapy030104 developmental biologymedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalebusinessmedicine.drug
researchProduct